Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes
- Conditions
- Type2 Diabetes
- Registration Number
- NCT03519529
- Brief Summary
Sex hormone-binding globulin(SHBG) is a surrogate marker of insulin resistance. This study aims at the characteristic and clinical significance of SHBG and testosterone in patients with type 2 diabetes(T2D).
- Detailed Description
The investigators recorded clinical factors, biochemical criterion such as serum levels of glucose and lipids, HbA1c, SHBG, testosterone, insulin, EPO, C-peptide, glucagon, microalbuminuria, glycemic variation via CGM, carotid plaque, ECG and ultrasonic cardiogram in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to Aprol 2018. The relationship between levels of SHBG, testosterone and glycemic variation/diabetic complications are analysed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 250
● Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.
- Patients use systemic steroidal anti-inflammatory drugs.
- Patients with an acute infection.
- Patients with acute complication of diabetes.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sex hormone-binding globulin Day 1 the blood sex hormone-binding globulin level of patients
- Secondary Outcome Measures
Name Time Method Testosterone Day 1 blood testosterone level of patients
EPO Day 1 blood erythropoietin level of patients
HbA1c Day 1 the glycosylated hemoglobin level of patients
MBG Day 1-4 24h mean blood glucose tested by CGM
MAGE Day 1-4 the 24h mean amplitude of glycemic excursion
SD Day 1-4 the standard deviation of mean glucose